TON - August 2020, Vol 13, No 4

TON June 2020, Vol 13, No 3 Cover

Circulating tumor DNA (ctDNA) analysis is a useful sequencing platform in metastatic castration-resistant prostate cancer (CRPC), and ctDNA alterations are detected in most patients with this type of prostate cancer, according to Justin Shaya, MD, Hematology/Oncology Fellow, UC San Diego Moores Cancer Center, CA. Read More ›

Preliminary results from a single-arm study demonstrated promising progression-free survival (PFS) and a clinically meaningful objective response rate (ORR) with the combination of pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane) as second- or third-line therapy in patients with advanced urothelial carcinoma. Read More ›

The COVID-19 pandemic is stretching into its fifth month in the United States, and patient advocacy groups continue to focus on providing the necessary support and services to patients with cancer. Read More ›

My Final Column as Editor-in-Chief
My first column as Editor-in-Chief was written for the inaugural issue of this publication, which was originally called The Oncology Nurse. Read More ›

Oncology nurses and nurse navigators are positioned on the front lines of care, playing an integral role in patients’ battles against cancer. Read More ›

Miami, FL—With too much red tape regarding genetic (ie, hereditary) testing, not enough people are being identified before they have breast cancer, according to Kevin Hughes, MD, FACS, Co-Director, Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Boston. Read More ›

Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting. Read More ›

Page 3 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: